Study of two oral chemo medicines for advanced bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two oral chemotherapy medicines (D07001 softgel plus Xeloda/TS-1) in people with advanced bile duct tract cancer that can’t be removed by surgery. It’s for situations where first-line gemcitabine plus cisplatin chemotherapy no longer worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older (or 20+ if you live in Taiwan).
- You have unresectable or metastatic bile tract cancer (cholangiocarcinoma, gallbladder cancer, or ampullary cancer).
- Your first chemotherapy (gemcitabine + cisplatin) didn’t work or you had to stop it.
- Your body is strong enough for treatment: ECOG performance status 0–1, and you have enough blood, liver, and kidney function.
- You have no major recent treatment overlap: no other chemotherapy since first-line, and the last chemo was within 60 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug, followed by targeted radiation, in people with bile duct or gallbladder cancer that cannot be removed with surgery. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new combination of three drugs (anlotinib, nab-paclitaxel, and S-1) for people with advanced bile duct or gallbladder cancer that has progressed after first-line chemotherapy. The goal is to see if this combination can help control the cancer better than standard second-line options.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
This trial tests a combination of two chemotherapy drugs (trifluridine/tipiracil and oxaliplatin) for people with advanced or metastatic bile duct cancer (including gallbladder cancer) who have only had one prior treatment. The goal is to see if this combination can help control the cancer.
This study tests a new drug called BL-B01D1 against standard treatment options for patients with advanced biliary tract cancer (cancer of the bile ducts) that has stopped responding to platinum chemotherapy and immunotherapy. The drug is designed to target and destroy cancer cells more effectively.
This trial tests a new combination of a drug that helps your immune system fight cancer, called sintilimab, along with chemotherapy. It is for people who have bile duct cancer or gallbladder cancer that has spread to other parts of the body and have not had treatment for this stage yet. The goal is to see if this combination helps shrink tumors or stops them from growing.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.